Haematology News and Research RSS Feed - Haematology News and Research

STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

Australian biopharmaceutical company Specialised Therapeutics Australia has struck an exclusive license and commercialisation agreement with European pharmaceutical partner company PharmaMar to market and distribute the novel oncology drug APLIDIN (plitidepsin) in Australia and New Zealand. [More]
Vascular side effects prevent first-line ponatinib use in chronic phase CML

Vascular side effects prevent first-line ponatinib use in chronic phase CML

Ponatinib is highly active when given to patients within 6 months of developing chronic phase chronic myeloid leukaemia, phase II results show, but its toxicity profile is unacceptable for first-line treatment. [More]
Hedgehog blockade promising in myeloid malignancies

Hedgehog blockade promising in myeloid malignancies

Phase I trial results published in The Lancet Haematology show that the hedgehog signalling pathway antagonist PF-04449913 is tolerable and has activity in patients with haematological cancers. [More]
Researchers establish safety, dosing of new drug for treating blood cancers

Researchers establish safety, dosing of new drug for treating blood cancers

Researchers at University of California, San Diego School of Medicine have established the safety and dosing of a new drug for treating blood cancers. The findings are published online July 27 in The Lancet Haematology. [More]
Oxford Gene Technology expands portfolio of fluorescence in situ hybridisation probes

Oxford Gene Technology expands portfolio of fluorescence in situ hybridisation probes

Oxford Gene Technology (OGT), The Molecular Genetics Company, is extending its portfolio of Cytocell® Pathology FISH probes with the addition of eight new probes. OGT offers the widest range of fluorescence in situ hybridisation (FISH) probes on the market, delivering a cost-effective and reliable solution for anyone engaged in FISH. [More]
Steroid-refractory chronic GVHD trial results ‘overestimate’ treatment efficacy

Steroid-refractory chronic GVHD trial results ‘overestimate’ treatment efficacy

Trial results for patients with steroid-refractory chronic graft versus host have overestimated the efficacies of treatments, suggests a meta-analysis published in The Lancet Haematology. [More]
Beckman Coulter announces expansion of Cellular Accessible Retroviral Evaluation Systems Initiative at International AIDS Society 2015

Beckman Coulter announces expansion of Cellular Accessible Retroviral Evaluation Systems Initiative at International AIDS Society 2015

Beckman Coulter Life Sciences today announces an expansion of its CARES (Cellular Accessible Retroviral Evaluation Systems) Initiative at the 2015 International AIDS Society (IAS) Conference, being held at the Vancouver Convention Centre from July 19-22, 2015 in Vancouver, Canada. CARES focuses on providing innovative solutions for the monitoring of HIV and AIDS treatment in Africa. [More]
Common arthritis drug could help to treat patients with blood cancers

Common arthritis drug could help to treat patients with blood cancers

Scientists at the University of Sheffield have discovered that a common drug given to arthritis sufferers could also help to treat patients with blood cancers. [More]
Sysmex unveils latest series of haematology analysers at IFCC congress

Sysmex unveils latest series of haematology analysers at IFCC congress

The Sysmex Corporation, the global leader in haematology, unveiled its latest series of haematology analysers at the annual IFCC congress, EuroMedLab JIB in Paris today. The XN-L series follows in the footsteps of its game-changing big brother, the XN-Series. The new, smaller XN-L Series makes top quality haematology available for all. [More]
Beckman Coulter brings new thinking to new lab challenges at EuroMedLab 2015

Beckman Coulter brings new thinking to new lab challenges at EuroMedLab 2015

Beckman Coulter Diagnostics supports IFCC-EFLM EuroMedLab 2015 with a showcase of solutions to improve workflow for the diagnostics laboratory. Held from 22-24 June 2015 at the Paris Palais des Congrès France, the company demonstrates its dedication to moving the clinical diagnostic lab forward with its total laboratory solution—from automation, chemistry, immunoassay and haematology to microbiology and its new molecular diagnostics system. [More]
NeoGenomics announces launch of new NeoLAB assays to diagnose hematologic diseases

NeoGenomics announces launch of new NeoLAB assays to diagnose hematologic diseases

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today the launch of its first twelve tests in a new line of "liquid biopsy" or NeoLAB assays using next generation sequencing and other advanced molecular technologies. [More]
EMA, ESMO and RCE joint workshop focuses on rare cancers and chordoma

EMA, ESMO and RCE joint workshop focuses on rare cancers and chordoma

To date, there is no drug approved for medical therapy of chordoma patients. Supporting research for chordoma (a very rare cancer arising from the skull base or the spine and affecting only one person in a million per year) was the focus of talks that took place on 30 April 2015 at the European Medicines Agency in London. The workshop was attended by patients, oncologists, pathologists, regulators, statisticians and industry representatives. [More]
Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes  in CLL/SLL patients

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

Today, Pharmacyclics LLC announced the results of the Phase III HELIOS trial (CLL3001), which found that patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who received ibrutinib (IMBRUVICA) in combination with bendamustine and rituximab (BR) experienced an 80% reduction in the risk of progression or death compared to patients receiving placebo in combination with BR. [More]
STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

Australian biopharmaceutical company Specialised Therapeutics Australia and Helsinn, a Swiss group focused on building quality cancer care, announce that the Therapeutic Goods Administration has approved AKYNZEO for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy. [More]
Researchers compile new genomic interactions catalogue

Researchers compile new genomic interactions catalogue

New clues about diseases like inflammatory bowel disorder may be found thanks to a new genomic interactions catalogue by a group of researchers in Japan and the United Kingdom. This research will be published on May 4, 2015 in Nature Genetics. [More]
T cell expansion technology: an interview with Alexander Malykhin, CVPF, University of Pennsylvania

T cell expansion technology: an interview with Alexander Malykhin, CVPF, University of Pennsylvania

T cells are taken from the patient’s blood and then modified using lentivirus, adenovirus or RNA electroporation. The modifications allow us to reprogram T cells to recognize cancer cells. [More]
HSCT use varies with region

HSCT use varies with region

A review of almost one million haematopoietic stem cell transplantation procedures has highlighted differences in the availability of the procedure and the use of autologous and allogeneic transplants across the world. [More]
Findings reveal variations between countries and regions in use of HSCT procedure

Findings reveal variations between countries and regions in use of HSCT procedure

Since the first experimental bone marrow transplant over 50 years ago, more than one million hematopoietic stem cell transplantations (HSCT) have been performed in 75 countries, according to new research charting the remarkable growth in the worldwide use of HSCT, published in The Lancet Haematology journal. [More]
Life-saving bone marrow transplants are not available to all who need them

Life-saving bone marrow transplants are not available to all who need them

Bone marrow (hematopoietic stem cell) transplant is a life saving treatment for patients with blood cancer that replaces blood stem cells lost to disease or chemotherapy. However, for each patient to benefit a matching donor must be found to provide the stem cells for transplant. [More]
Second-line bosutinib well tolerated by Japanese patients

Second-line bosutinib well tolerated by Japanese patients

Phase I/II clinical trial data support the use of bosutinib as second- or third-line tyrosine kinase inhibitor therapy in Japanese patients with Philadelphia chromosome-positive chronic myeloid leukaemia. [More]
Advertisement
Advertisement